Ocular Therapeutix, Inc. provided earnings guidance for the fiscal year 2022. For the period, the company expects total net product revenue to be in the range of $48 to $52 million, representing growth of between 10% to 20% over 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.315 USD | +2.35% | +10.99% | +40.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.36% | 956M | |
+34.40% | 693B | |
+29.39% | 584B | |
-2.95% | 372B | |
+20.60% | 332B | |
+6.63% | 294B | |
+14.11% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.82% | 168B |
- Stock Market
- Equities
- OCUL Stock
- News Ocular Therapeutix, Inc.
- Ocular Therapeutix, Inc. Provides Earnings Guidance for the Fiscal Year 2022